Sumitomo Dainippon to invest 700 million yen in cyborg technology

17 October 2018

Sumitomo Dainippon Pharma (TYO: 4506) has announced a 700 million yen ($6 million) investment in a company that aims to enhance the functionality of cyborg technologies and the combination of bio-signal processing and robotics.

The drugmaker has also signed a research and development agreement with fellow Japanese firm MELTIN, which has the overriding objective of allowing humans to transcend their physical restriction and unleash their creativity for creating a world where they can live happily and freely.

Sumitomo, which is more ordinarily focused on researching psychiatry and neurology, oncology, cell therapies and regenerative medicine, has nonetheless also looked beyond the traditional world of pharma to identify additional healthcare areas that it sees as new business opportunities, calling them ‘frontier areas’.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK